Exhibit 99.2

EXPRESS SCRIPTS AND MEDCO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

On July 20, 2011, Express Scripts, Inc. (“Express Scripts”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Medco Health Solutions, Inc. (“Medco”), Aristotle Holding, Inc. (“New Express Scripts”), Aristotle Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of New Express Scripts (“Express Scripts Merger Sub”), and Plato Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of New Express Scripts (“Medco Merger Sub” and, together with Express Scripts Merger Sub, the “Merger Subs”), which was amended by Amendment No. 1 thereto on November 7, 2011. Pursuant to the Merger Agreement, Express Scripts Merger Sub will be merged with and into Express Scripts (the “Express Scripts Merger”), and Medco Merger Sub will be merged with and into Medco (the “Medco Merger” and, together with the Express Scripts Merger, the “Mergers”). As a result, Express Scripts and Medco will each become a wholly owned subsidiary of New Express Scripts. The “Related Financing Transactions” refers to (i) the borrowing by us of $4.0 billion under the Term Loan Facility (as defined below), the issuance by New Express Scripts on November 21, 2011 of $900 million aggregate principal amount of 2.750% Senior Notes due 2014 (the “2014 Notes”), $1.25 billion aggregate principal amount of 3.500% Senior Notes due 2016 (the “2016 Notes”), $1.25 billion aggregate principal amount of 4.750% Senior Notes due 2021 (the “2021 Notes”) and $700 million aggregate principal amount of 6.125% Senior Notes due 2021 (together with the 2014 Notes, the 2016 Notes and the 2021 Notes, the “Existing New Express Scripts Notes”) and each of the other borrowings, issuances or other transactions effected to procure the balance of the funds needed to pay the cash consideration payable to Medco stockholders in accordance with the Merger Agreement, to repay any existing indebtedness that will be repaid in connection with the Mergers and to pay related fees and expenses and (ii) the payment of existing indebtedness that will be repaid in connection with the Mergers.

The unaudited pro forma condensed combined financial information presented below is derived from the historical financial statements of Express Scripts and Medco, adjusted to give effect to the Mergers and the Related Financing Transactions.

The unaudited pro forma condensed combined statements of operations for the nine months ended September 30, 2011 and for the year ended December 31, 2010 give effect to the Mergers and the Related Financing Transactions as if they had occurred on the first day of the earliest period presented. The unaudited pro forma condensed combined balance sheet gives effect to the Mergers and the Related Financing Transactions as if they had occurred on September 30, 2011.

The pro forma adjustments are preliminary and have been made solely for informational purposes. The actual results reported by the combined company in periods following the Mergers may differ significantly from that reflected in these unaudited pro forma condensed combined financial statements for a number of reasons, including but not limited to cost savings from operating efficiencies, synergies and the impact of the incremental costs incurred in integrating the two companies. As a result, the pro forma condensed combined information is not intended to represent and does not purport to be indicative of what the combined company’s financial condition or results of operations would have been had the Mergers and the Related Financing Transactions been completed on the applicable dates of this pro forma condensed combined financial information. In addition, the pro forma condensed combined financial information does not purport to project the future financial condition and results of operations of the combined company.

The unaudited pro forma condensed combined financial information is based upon the historical financial statements of Express Scripts and Medco. The pro forma condensed combined financial statements are based on various assumptions, including assumptions relating to the consideration paid and the allocation thereof to the assets acquired and liabilities assumed from Medco based on preliminary estimates of fair value. The pro forma assumptions and adjustments are described in the accompanying notes presented on the following pages. Pro forma adjustments are those that are directly attributable to the transaction, are factually supportable and, with respect to the unaudited pro forma condensed combined statement of operations, are expected to have a continuing impact on the consolidated results. The final purchase price and the allocation thereof will differ from that reflected in the pro forma condensed combined financial statements after final valuation procedures are performed and amounts are finalized following the completion of the Mergers.

The unaudited pro forma condensed combined financial information does not reflect any cost savings from operating efficiencies, synergies or other restructurings that could result from the Mergers.

1

Unaudited Pro Forma Condensed Combined Balance Sheet

September 30, 2011

See accompanying notes to the unaudited pro forma condensed combined financial statements.

2

Unaudited Pro Forma Condensed Combined Statement of Operations

For the Nine Months Ended September 30, 2011

See accompanying notes to the unaudited pro forma condensed combined financial statements.

3

Unaudited Pro Forma Condensed Combined Statement of Operations

For the Fiscal Year Ended December 31, 2010

See accompanying notes to the unaudited pro forma condensed combined financial statements.

4

Notes to Unaudited Pro Forma Condensed Combined Financial Statements

Note 1 — Basis of Presentation

The unaudited pro forma condensed combined financial information was prepared using the acquisition method of accounting and was based on the historical audited financial statements of Express Scripts and Medco for the years ended December 31, 2010 and December 25, 2010, respectively, and unaudited financial statements of Express Scripts and Medco as of and for the nine months ended September 30, 2011 and September 24, 2011, respectively. Certain reclassifications have been made to the historical financial statements of Medco to conform to Express Scripts’ presentation, including the presentation of claims and rebates payable as a separate line item from accounts payable and condensing Medco’s receivable balances into one line item. Additionally, Medco’s product revenues and service revenues have been combined into a single line item and amortization of intangibles has been included in selling, general and administrative expenses to conform to Express Scripts’ presentation. Finally, the following adjustments have been made to cost of revenues and selling, general and administrative expense:

The unaudited pro forma condensed combined statements of operations for the year ended December 31, 2010 and for the nine months ended September 30, 2011 give effect to the proposed Mergers and the Related Financing Transactions as if they had occurred on the first day of the earliest period presented. The unaudited condensed combined balance sheet as of September 30, 2011 gives effect to the Mergers and the Related Financing Transactions as if they had occurred on September 30, 2011.

The acquisition method of accounting is based on authoritative guidance for business combinations and uses the fair value concepts defined in authoritative guidance. We prepared the unaudited pro forma condensed combined financial information using the acquisition method of accounting under these existing U.S. GAAP standards.

The authoritative guidance for business combinations requires, among other things, that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date if fair value can reasonably be estimated. If the fair value of an asset or liability that arises from a contingency cannot be determined, the asset or liability is recognized if it is probable that an asset existed or a liability has been incurred at the acquisition date and the amount of such asset or liability can be reasonably determined. In addition, the guidance establishes that the consideration transferred be measured at the closing date of the acquisition at the then-current market price. As the purchase price includes shares to be issued for consideration in the Mergers, this will likely result in an equity component that is different from the amount assumed in these unaudited pro forma condensed combined financial statements.

5

The authoritative guidance for fair value defines the term “fair value,” sets forth the valuation requirements for any asset or liability measured at fair value, expands related disclosure requirements and specifies a hierarchy of valuation techniques based on the nature of inputs used to develop the fair value measures. Fair value is defined in the guidance as “the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.” This is an exit price concept for the valuation of the asset or liability. In addition, market participants are assumed to be buyers and sellers in the principal (or the most advantageous) market for the asset or liability. Fair value measurements for an asset assume the highest and best use by these market participants. As a result of these standards, we may be required to record assets that we do not intend to use or sell (defensive assets) and/or to value assets at fair value measurements that do not reflect our intended use of those assets. Many of these fair value measurements can be highly subjective and it is also possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts.

The pro forma adjustments described below have been developed based on assumptions and estimates, including assumptions relating to the consideration to be paid and the allocation thereof to the assets acquired and liabilities assumed from Medco based on preliminary estimates of fair value. The final purchase price and the allocation thereof will differ from that reflected in the pro forma condensed combined financial statements after final valuation procedures are performed and amounts are finalized following the completion of the Mergers.

The unaudited pro forma condensed combined financial statements are provided for illustrative purposes only and do not purport to represent what the actual consolidated results of operations or the consolidated financial position of New Express Scripts would have been had the Mergers and the Related Financing Transactions occurred on the dates assumed, nor are they necessarily indicative of future consolidated results of operations or financial position.

The unaudited pro forma condensed combined financial statements do not reflect any cost savings from operating efficiencies, synergies or other restructurings that could result from the Mergers. Additionally, no adjustments were made to reflect termination costs to be incurred in connection with the Mergers, as such costs are not currently factually supportable.

Express Scripts has been determined to be the acquirer under the acquisition method of accounting based on various considerations. Upon closing of the Mergers, Express Scripts stockholders are expected to own approximately 59% of the combined company and Medco stockholders are expected to own approximately 41%. Additionally, New Express Scripts will transfer cash and issue common stock as the merger consideration to Medco stockholders. Further, the Board of Directors and senior management of the combined company will be comprised primarily of current Express Scripts board members and senior management, respectively.

Express Scripts performed a preliminary review of Medco’s accounting policies, based primarily on publicly available information, to determine whether any adjustments were necessary to ensure comparability in the pro forma condensed combined financial statements. At this time, Express Scripts is not aware of any differences that would have a material impact on the pro forma condensed combined financial statements. The unaudited pro forma condensed combined financial statements do not reflect any differences in accounting policies. Upon completion of the Mergers, or as more information becomes available, Express Scripts will perform a more detailed review of Medco’s accounting policies. As a result of that review, differences may be identified between the accounting policies of the two companies that, when conformed, could have a material impact on the combined financial statements.

Note 2 — Preliminary Purchase Price

The total consideration for the transaction is $28.4 billion, composed of $70.72 per share in cash and New Express Scripts’ stock (valued based on the closing price of Express Scripts stock on February 2, 2012), including $28.80 in cash and 0.81 shares for each Medco share outstanding. The purchase price for the business combination is estimated as follows:

6

Since the Express Scripts stock price at the February 2, 2012 measurement date used for purposes of these unaudited pro forma condensed combined financial statements exceeds the average stock price for the 15 days prior to and including such measurement date, which is used to calculate the exchange ratio, excess fair value of $26.4 million is recorded for the replacement stock options. For the purposes of the unaudited pro forma condensed combined statements of operations, this excess fair value has been amortized over the remaining vesting period of the stock options resulting in additional compensation expense of $16.1 million and $5.5 million for the year ended December 31, 2010 and the nine months ended September 30, 2011, respectively. Express Scripts will recalculate the fair values of the Medco stock options and the converted options as of the closing date to determine the excess fair value amounts, if any, to be recorded as compensation expense by New Express Scripts.

Medco’s stock incentive plan includes a provision for the acceleration of vesting of awards granted under the Medco stock incentive plan in certain circumstances involving termination in connection with a change in control. No adjustments have been made to the unaudited pro forma condensed combined financial statements as a result of this provision, as Express Scripts cannot currently predict the nature and extent of terminations to be made in connection with the Mergers.

The portion of the purchase price to be paid in shares of New Express Scripts common stock is valued based on the number of Medco shares outstanding immediately prior to the Mergers and the Express Scripts share price on that date. A 10% difference in Express Scripts’ stock price would change the purchase price by approximately $1.8 billion with a corresponding change to goodwill. Additionally, a 10% change in the number of Medco shares outstanding would change the purchase price by approximately $2.7 billion, with a corresponding change to goodwill. The actual purchase price will fluctuate with the price of Express Scripts’ common stock until the effective date of the acquisition and the final valuation could differ significantly from the current estimate.

Note 3 — Preliminary Purchase Price Allocation

The combined company will allocate the purchase price paid by Express Scripts to the fair value of the Medco assets acquired and liabilities assumed. The pro forma purchase price allocation below has been developed based on preliminary estimates of fair value using the historical financial statements of Medco as of September 24, 2011. In addition, the allocation of the purchase price to acquired intangible assets is based on preliminary fair value estimates and is subject to final management analysis, with the assistance of third party valuation advisors, at the completion of the Mergers. Once Express Scripts and its third party valuation

7

advisors have full access to the specifics of Medco’s intangible assets, additional insight will be gained that could impact: (i) the estimated total value assigned to intangible assets, (ii) the estimated allocation of value between finite-lived and indefinite-lived intangible assets and/or (iii) the estimated weighted-average useful life of each category of intangible assets. The estimated intangible asset values and their useful lives could be impacted by a variety of factors that may become known to us only upon access to additional information and/or by changes in such factors that may occur prior to the effective time of the Mergers.

The estimated intangible assets are comprised of customer contracts with an estimated useful life of 10 years and trade names with an estimated useful life of 5 years, which is consistent with the estimated benefit period. Since Express Scripts has limited information at this time to value all of the intangible assets, the estimated fair values were based primarily on current estimates of Medco’s expected future cash flows for all customer contracts and trade names. Express Scripts expects that the estimated value assigned to Medco’s customer contracts is likely to change as access is gained by Express Scripts to the specifics of Medco’s customer contracts and as life and renewal assumptions are refined. Additional intangible asset classes may be identified as the valuation process continues, however such items are currently not expected to be material to the overall purchase price allocation. A 10% change in the amount allocated to identifiable intangible assets would increase or decrease annual amortization expense by $140.0 million. The residual amount of the purchase price after preliminary allocation to identifiable intangibles has been allocated to goodwill. The actual amounts recorded when the Mergers are complete may differ materially from the pro forma amounts presented below (in millions):

Note 4 — Unaudited Pro Forma Adjustments

Unaudited Pro Forma Condensed Combined Balance Sheet

(A) Sources and Uses

8

In connection with the Mergers, on August 5, 2011, Express Scripts entered into a $14.0 billion unsecured bridge facility (the “Bridge Facility”). The lenders’ commitments under the Bridge Facility have been subsequently reduced to $5.9 billion. On the effective date of the Bridge Facility and prior to the consummation of the Express Scripts Merger, Express Scripts will be the borrower under the Bridge Facility. New Express Scripts will assume the role, rights and obligations of Express Scripts and become the borrower under the Bridge Facility upon consummation of the Express Scripts Merger. The Bridge Facility will be available for Express Scripts or New Express Scripts to pay a portion of the cash consideration in accordance with the Merger Agreement, to repay any existing indebtedness that will become due or otherwise default upon consummation of the Mergers, and to pay related fees and expenses. When any senior notes are issued, the commitments under the Bridge Facility will be automatically reduced dollar-for-dollar by the net proceeds of such senior notes.

In connection with the Mergers, on August 29, 2011, Express Scripts entered into a $5.5 billion permanent facility consisting of a five-year $4.0 billion unsecured term loan facility (the “Term Loan Facility”) and a five-year unsecured $1.5 billion revolving loan facility (the “Revolving Loan Facility”). On the effective date of the Term Loan Facility and the Revolving Loan Facility and prior to the consummation of the Express Scripts Merger, Express Scripts will be the borrower under the Term Loan Facility and the Revolving Loan Facility. New Express Scripts will assume the role, rights and obligations of Express Scripts and become the borrower under the credit agreement in respect of the Term Loan Facility and the Revolving Loan Facility upon consummation of the Express Scripts Merger. The Term Loan Facility will be available for Express Scripts to pay a portion of the cash consideration in accordance with the Merger Agreement, to repay any existing indebtedness that will become due or otherwise default upon consummation of the Mergers and to pay related fees and expenses. The Revolving Loan Facility will be available for working capital needs and general corporate purposes. Upon entry into the Term Loan Facility, the commitments under the Bridge Facility were automatically reduced by $4.0 billion. Upon funding of the Term Loan Facility, we anticipate that the $1.5 billion Revolving Loan Facility will replace Express Scripts’ current $750 million revolving credit facility.

On November 21, 2011, New Express Scripts issued $4.1 billion aggregate principal amount of senior notes (the Existing New Express Scripts Notes), the net proceeds of which will be used to pay a portion of the cash consideration payable to Medco stockholders in accordance with the Merger Agreement, to repay any existing indebtedness that will be repaid in connection with the Mergers and to pay related fees and expenses. The commitments under the Bridge Facility were reduced dollar-for-dollar by the net proceeds of the issuance of the Existing New Express Scripts Notes.

The net proceeds of any issuance of senior notes, together with our borrowings under the Term Loan Facility, the net proceeds from the sale of the Existing New Express Scripts Notes and cash on hand, will be used to pay all or a portion of the cash consideration payable to Medco stockholders in accordance with the Merger Agreement, to repay any existing indebtedness that will be repaid in connection with the Mergers and to pay related fees and expenses. We may also finance a portion of these obligations through borrowings under the Bridge Facility and/or our Revolving Loan Facility. In the event that we draw upon the Bridge Facility, we may refinance all or a portion of the Bridge Facility at a later date.

The sources of funds table above assumes that we will use $1.0 billion of cash on hand at September 30, 2011 to pay a portion of the consideration in connection with the Mergers. Actual cash on hand used in connection with the Mergers may vary depending on the timing of the closing of the Mergers and other factors, which would increase or decrease the amount of funds that we borrow to fund the Mergers.

(B) Debt

Upon close of the Mergers, Express Scripts intends to settle Medco’s $2.0 billion of current debt outstanding under its unsecured credit agreements.

The adjustment to long-term debt is comprised of the following items (in millions):

The fair values of Medco’s senior notes were estimated based on observable relevant market information.

Additionally, deferred financing fees of $3.7 million and $11.4 million relating to pre-Merger Medco debt have been eliminated from Prepaid expenses and other current assets and Other assets, respectively, in connection with the adjustment of Medco’s debt to fair value.

9

(C) Property and equipment, net

Based on the preliminary fair value assessment, the carrying value of Medco’s property and equipment at September 24, 2011 approximates fair value. As such, the carrying value of Medco’s property and equipment was used in the preliminary purchase price allocation, and no adjustments were made to the unaudited pro forma condensed combined balance sheet. Adjustments may be required when additional information is obtained and a more detailed review is performed over the fair value of property and equipment. The actual amounts recorded when the Mergers are completed may differ materially from the current book value of property and equipment.

(D) Goodwill and other intangible assets

The net adjustment to goodwill includes the elimination of Medco pre-Merger goodwill balances and is calculated as follows (in millions):

The net adjustment to other intangible assets, net, is calculated as follows (in millions):

See Note 3 for the estimated purchase price allocation. The final valuation could differ significantly from the current estimate. The pro forma purchase price allocation is preliminary as the Mergers have not yet been completed. The pro forma presentation assumes that the historical values of Medco’s tangible assets and liabilities approximate fair value. Additionally, the allocation of the purchase price to acquired intangible assets is preliminary and subject to the final outcome of management’s analysis to be conducted, with the assistance of valuation advisors, upon the completion of the Mergers. The residual amount of the purchase price has been allocated to goodwill. The actual amounts recorded when the Mergers are completed may differ materially from the pro forma amounts presented herein.

(E) Deferred taxes

The adjustment reflects an increase of $3,621.8 million in deferred tax liabilities associated with the recording of new identifiable intangible assets for the combined company. This amount was calculated using a tax rate of 38.18%, which represents Express Scripts’ and Medco’s estimated blended rate for the first nine months of 2011, which approximates the relevant statutory rate. This was offset by an additional adjustment of $378.3 million associated with the portion of replacement stock options and restricted stock units allocated to the purchase price. The actual amounts recorded for deferred taxes may differ materially from the pro forma amounts presented herein.

10

(F) Equity

The historical stockholders’ equity of Medco will be eliminated upon the completion of the Mergers. The total stockholders’ equity of the combined company will be increased over the pre-Merger Express Scripts amounts by the value of the common stock issued in connection with the purchase price. New Express Scripts will be issuing approximately $17.2 billion of stock as part of the purchase price consideration. The calculation below estimates the number of shares issued to be 313.8 million using a share price of $51.75 (Express Scripts’ closing share price on February 2, 2012), and the number of replacement stock options and restricted stock units to be 53.9 million. The number of shares issued is dependent on the number of Medco shares, restricted shares and options outstanding on the date of the Mergers. See the calculation of the pro forma adjustments to common stock and additional paid-in capital below (in millions):

Unaudited Pro Forma Condensed Combined Statements of Operations

(G) Revenues and Cost of revenues

Adjustments have been included in the unaudited pro forma condensed combined statements of operations to eliminate revenues and cost of revenues from transactions between Express Scripts and Medco. Express Scripts and Medco’s pharmacies may be included in the pharmacy networks of the other respective company in order to fulfill members’ prescriptions for certain drugs that are under limited or exclusive distribution contracts with manufacturers.

(H) Selling, general and administrative

11

(I) Interest Expense

For the purposes of the unaudited pro forma condensed combined financial statements, Express Scripts is assumed to partially fund the Mergers through drawing $4.0 billion under the Term Loan Facility, using the approximately $4.1 billion of net proceeds from the Existing New Express Scripts Notes and any future issuance of senior notes and drawing up to $5.9 billion under the Bridge Facility, reduced on a dollar-for-dollar basis in an amount equal to the net proceeds from any further issuance of senior notes. The adjustment included in the unaudited pro forma condensed combined statements of operations reflects the additional interest expense using an estimated weighted average interest rate of 3.84% for the nine months ended September 30, 2011 and 3.81% for the twelve months ended December 31, 2010. For purposes of estimating the weighted average interest rate, we have made certain assumptions regarding the Related Financing Transactions. The actual weighted average interest rate may differ from the estimated rate due to changes in market conditions or differences between the actual terms of any debt financing and our assumptions. The estimated interest rates for the Bridge Facility and the Term Loan Facility were calculated using the prime rate plus a margin of 0.50%, based on our consolidated leverage ratio as of September 30, 2011. The interest rate for the Bridge Facility also assumes that the margin will increase by 0.25% on the 90th day after the funding date and by an additional 0.25% every 90 days thereafter, per the terms of the credit agreement in respect of the Bridge Facility. Adjustments have also been made for the historical interest expense related to Medco’s $2.0 billion of debt outstanding under its unsecured credit agreements that we anticipate will be repaid at the closing of the Mergers.

The adjustment to interest expense reflects the following (in millions):

(J) Income taxes

The pro forma condensed combined income tax provision has been adjusted for the tax effect of adjustments to income before income taxes at the estimated blended effective rate for the periods presented as the effective rate approximates the statutory rate for the periods presented. The effective tax rate of the combined company could be significantly different depending on post-acquisition activities.

12

(K) Basic and diluted shares

The unaudited pro forma condensed combined basic and diluted earnings per share calculations are based on the combined basic and diluted weighted-average shares. The historical basic and diluted weighted average shares of Medco are assumed to be replaced by the shares expected to be issued by New Express Scripts at an exchange ratio of 0.81 per Medco share.

13